IDH2 and central nervous system cancer: Conclusively, our study demonstrates that three radiomic models based on pre-operative MR data for noninvasive, individualized prediction of IDH mutation, 1p/19q codeletion, and TERT promoter mutation in gliomas patients regardless of grades.